Jeremy Tomlinson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3913950/publications.pdf

Version: 2024-02-01

178 papers	14,227 citations	25034 57 h-index	21540 114 g-index
184 all docs	184 docs citations	184 times ranked	13896 citing authors

#	Article	IF	Citations
1	Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet, The, 2016, 387, 679-690.	13.7	1,397
2	Association between premature mortality and hypopituitarism. Lancet, The, 2001, 357, 425-431.	13.7	930
3	11Î²-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response. Endocrine Reviews, 2004, 25, 831-866.	20.1	897
4	Pathogenesis of non-alcoholic fatty liver disease. QJM - Monthly Journal of the Association of Physicians, 2010, 103, 71-83.	0.5	581
5	Non-alcoholic fatty liver disease and diabetes. Metabolism: Clinical and Experimental, 2016, 65, 1096-1108.	3.4	396
6	Mortality in Patients with Pituitary Disease. Endocrine Reviews, 2010, 31, 301-342.	20.1	331
7	Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. Journal of Hepatology, 2016, 64, 399-408.	3.7	308
8	Diagnosis and management of adrenal insufficiency. Lancet Diabetes and Endocrinology,the, 2015, 3, 216-226.	11.4	297
9	Mutations in the genes encoding 11Î²-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nature Genetics, 2003, 34, 434-439.	21.4	276
10	Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ: British Medical Journal, 2010, 341, c2701-c2701.	2.3	257
11	Systematic review: the diagnosis and staging of nonâ€alcoholic fatty liver disease and nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2011, 33, 525-540.	3.7	254
12	Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1027-1036.	3.6	231
13	11Î²-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2482-91.	7.1	225
14	Regulation of Expression of 11Î²-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue: Tissue-Specific Induction by Cytokines*. Endocrinology, 2001, 142, 1982-1989.	2.8	215
15	Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data metaâ€analysis of the LEAD program. Alimentary Pharmacology and Therapeutics, 2013, 37, 234-242.	3.7	204
16	Expression of 11Î²-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue Is Not Increased in Human Obesity. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5630-5635.	3.6	196
17	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight, 2017, 2, .	5.0	187
18	Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. Journal of Clinical Investigation, 2015, 125, 501-520.	8.2	163

#	Article	IF	Citations
19	Androgen generation in adipose tissue in women with simple obesity â€“ a site-specific role for 17Î²-hydroxysteroid dehydrogenase type 5. Journal of Endocrinology, 2004, 183, 331-342.	2.6	154
20	11Î²-Hydroxysteroid Dehydrogenase Type 1 Activity in Lean and Obese Males with Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4755-4761.	3.6	153
21	Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11Î²-hydroxysteroid dehydrogenase type 1. Journal of Molecular Endocrinology, 2005, 34, 675-684.	2.5	153
22	11Î²-Hydroxysteroid Dehydrogenase 1: Translational and Therapeutic Aspects. Endocrine Reviews, 2013, 34, 525-555.	20.1	152
23	11Î²-Hydroxysteroid Dehydrogenase Type 1 Regulates Glucocorticoid-Induced Insulin Resistance in Skeletal Muscle. Diabetes, 2009, 58, 2506-2515.	0.6	146
24	Nonclassic Lipoid Congenital Adrenal Hyperplasia Masquerading as Familial Glucocorticoid Deficiency. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3865-3871.	3.6	138
25	Glucocorticoids and non-alcoholic fatty liver disease. Journal of Steroid Biochemistry and Molecular Biology, 2015, 154, 94-103.	2.5	137
26	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocrine Reviews, 2020, 41, 66-117.	20.1	134
27	AKR1C3-Mediated Adipose Androgen Generation Drives Lipotoxicity in Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3327-3339.	3.6	133
28	Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5Î±-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 161-171.	3.6	131
29	Cortisol metabolism and the role of 11Î²-hydroxysteroid dehydrogenase. Best Practice and Research in Clinical Endocrinology and Metabolism, 2001, 15, 61-78.	4.7	129
30	The Long-Term Predictive Accuracy of the Short Synacthen (Corticotropin) Stimulation Test for Assessment of the Hypothalamic-Pituitary-Adrenal Axis. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 43-47.	3.6	125
31	Understanding androgen action in adipose tissue. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 277-284.	2.5	120
32	Impaired Glucose Tolerance and Insulin Resistance Are Associated With Increased Adipose 11Î²-Hydroxysteroid Dehydrogenase Type 1 Expression and Elevated Hepatic 5Î±-Reductase Activity. Diabetes, 2008, 57, 2652-2660.	0.6	117
33	Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol. European Journal of Endocrinology, 2015, 173, 633-642.	3.7	116
34	Regulation of Lipogenesis by Glucocorticoids and Insulin in Human Adipose Tissue. PLoS ONE, 2011, 6, e26223.	2.5	112
35	Increased 5Î±-Reductase Activity and Adrenocortical Drive in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3558-3566.	3.6	97
36	Guidelines for the management of glucocorticoids during the periâ€operative period for patients with adrenal insufficiency. Anaesthesia, 2020, 75, 654-663.	3.8	93

#	Article	IF	Citations
37	Inhibition of 11Î²-Hydroxysteroid Dehydrogenase Type 1 Activity in Vivo Limits Glucocorticoid Exposure to Human Adipose Tissue and Decreases Lipolysis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 857-864.	3.6	92
38	Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism, 2011, 13, 692-702.	4.4	92
39	Development of Hepatocellular Carcinoma in a Murine Model of Nonalcoholic Steatohepatitis Induced by Use of a High-Fat/Fructose Diet and Sedentary Lifestyle. American Journal of Pathology, 2014, 184, 1550-1561.	3.8	91
40	Weight Loss Increases 11Î²-Hydroxysteroid Dehydrogenase Type 1 Expression in Human Adipose Tissue. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2711-2716.	3.6	85
41	Cerebrospinal Fluid Corticosteroid Levels and Cortisol Metabolism in Patients with Idiopathic Intracranial Hypertension: A Link between 11Î²-HSD1 and Intracranial Pressure Regulation?. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5348-5356.	3.6	84
42	A Switch in Hepatic Cortisol Metabolism across the Spectrum of Non Alcoholic Fatty Liver Disease. PLoS ONE, 2012, 7, e29531.	2.5	83
43	A novel selective 11Î²-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. Journal of Endocrinology, 2008, 197, 297-307.	2.6	80
44	Mechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders. European Journal of Endocrinology, 2013, 169, R27-R37.	3.7	80
45	Central Hypoadrenalism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4027-4036.	3.6	80
46	Reduced Glucocorticoid Production Rate, Decreased 5Â-Reductase Activity, and Adipose Tissue Insulin Sensitization After Weight Loss. Diabetes, 2008, 57, 1536-1543.	0.6	79
47	Steroid Biomarkers and Genetic Studies Reveal Inactivating Mutations in Hexose-6-Phosphate Dehydrogenase in Patients with Cortisone Reductase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3827-3832.	3.6	79
48	Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut, 2012, 61, 484-500.	12.1	71
49	Elevated cerebrospinal fluid (CSF) leptin in idiopathic intracranial hypertension (IIH): evidence for hypothalamic leptin resistance?. Clinical Endocrinology, 2009, 70, 863-869.	2.4	69
50	Mechanisms of Disease: selective inhibition of 11Î²-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. Nature Clinical Practice Endocrinology and Metabolism, 2005, 1, 92-99.	2.8	68
51	Loss of 5Î±-Reductase Type 1 Accelerates the Development of Hepatic Steatosis but Protects Against Hepatocellular Carcinoma in Male Mice. Endocrinology, 2013, 154, 4536-4547.	2.8	67
52	Gender-Specific Differences in Skeletal Muscle 11Î²-HSD1 Expression Across Healthy Aging. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2673-2681.	3.6	67
53	PYY plays a key role in the resolution of diabetes following bariatric surgery in humans. EBioMedicine, 2019, 40, 67-76.	6.1	65
54	11Î²-HYDROXYSTEROID DEHYDROGENASE TYPE 1 IN DIFFERENTIATING OMENTAL HUMAN PREADIPOCYTES: FROM DE-ACTIVATION TO GENERATION OF CORTISOL. Endocrine Research, 2002, 28, 449-461.	1.2	64

#	Article	IF	Citations
55	Regulation of Expression of 11Â-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue: Tissue-Specific Induction by Cytokines. Endocrinology, 2001, 142, 1982-1989.	2.8	63
56	Growth Hormone, Insulin-Like Growth Factor-I and the Cortisol-Cortisone Shuttle. Hormone Research in Paediatrics, 2001, 56, 1-6.	1.8	61
57	Absence of Cushingoid Phenotype in a Patient with Cushingâ€™s Disease due to Defective Cortisone to Cortisol Conversion. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 57-62.	3.6	61
58	Lack of Significant Metabolic Abnormalities in Mice with Liver-Specific Disruption of 11Î²-Hydroxysteroid Dehydrogenase Type 1. Endocrinology, 2012, 153, 3236-3248.	2.8	61
59	Glucocorticoid Modulation of Insulin Signaling in Human Subcutaneous Adipose Tissue. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4332-4339.	3.6	60
60	The Endocrine and Metabolic Characteristics of a Large Bardet-Biedl Syndrome Clinic Population. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1834-1841.	3.6	58
61	A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. JCI Insight, 2019, 4, .	5.0	55
62	Expression profiling of 11Î²-hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes. Journal of Molecular Endocrinology, 2006, 37, 327-340.	2.5	53
63	Modulation of glucocorticoid action and the treatment of type-2 diabetes. Best Practice and Research in Clinical Endocrinology and Metabolism, 2007, 21, 607-619.	4.7	53
64	Glucocorticoids Fail to Cause Insulin Resistance in Human Subcutaneous Adipose Tissue In Vivo. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1631-1640.	3.6	53
65	Baseline morning cortisol level as a predictor of pituitaryâ€“adrenal reserve: a comparison across three assays. Clinical Endocrinology, 2017, 86, 177-184.	2.4	53
66	AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2019, 99, 67-80.	3.4	52
67	11Î²-Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. Diabetologia, 2008, 51, 2003-2011.	6.3	51
68	Dehydroepiandrosterone exerts antiglucocorticoid action on human preadipocyte proliferation, differentiation, and glucose uptake. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E1134-E1144.	3.5	50
69	Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with nonâ€alcoholic steatohepatitis. Diabetes, Obesity and Metabolism, 2014, 16, 651-660.	4.4	50
70	Dual-5Î±-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 103-113.	3.6	50
71	11Î²-Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function. Journal of Biological Chemistry, 2007, 282, 27030-27036.	3.4	48
72	The Short Synacthen (Corticotropin) Test Can Be Used to Predict Recovery of Hypothalamo-Pituitary-Adrenal Axis Function. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3050-3059.	3.6	48

#	Article	IF	Citations
73	A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterology, 2019, 10, 337-346.	1.8	48
74	Absence of Cushingoid Phenotype in a Patient with Cushing's Disease due to Defective Cortisone to Cortisol Conversion. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 57-62.	3.6	48
75	Depot-specific prostaglandin synthesis in human adipose tissue: A novel possible mechanism of adipogenesis. Gene, 2006, 380, 137-143.	2.2	46
76	11Î²-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. Brain Communications, 2020, 2, fcz050.	3.3	46
77	Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clinical Endocrinology, 2022, 96, 200-219.	2.4	46
78	Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension. JCI Insight, 2021, 6, .	5.0	45
79	11Î²-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs, 2010, 19, 1067-1076.	4.1	44
80	Guidance for the prevention and emergency management of adult patients with adrenal insufficiency. Clinical Medicine, 2020, 20, 371-378.	1.9	44
81	Cortisol, 11Î²-hydroxysteroid dehydrogenase type 1 and central obesity. Trends in Endocrinology and Metabolism, 2002, 13, 94-96.	7.1	43
82	Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome. Lancet, The, 2015, 385, S16.	13.7	43
83	Corticosteroids, 11?-Hydroxysteroid Dehydrogenase Isozymes and the Rabbit Choroid Plexus. Journal of Neuroendocrinology, 2007, 19, 614-620.	2.6	42
84	Evaluating the Fat Distribution in Idiopathic Intracranial Hypertension Using Dual-Energy X-ray Absorptiometry Scanning. Neuro-Ophthalmology, 2018, 42, 99-104.	1.0	42
85	Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open, 2013, 3, e003995.	1.9	41
86	Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 33-41.	0.5	41
87	Low-Dose Growth Hormone Inhibits 11Î²-Hydroxysteroid Dehydrogenase Type 1 but Has No Effect upon Fat Mass in Patients with Simple Obesity. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2113-2118.	3.6	39
88	11Î²HSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 174-187.	3.6	39
89	The Functional Consequences of 11Î²-Hydroxysteroid Dehydrogenase Expression in Adipose Tissue. Hormone and Metabolic Research, 2002, 34, 746-751.	1.5	38
90	5Î±-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes. Endocrinology, 2015, 156, 2863-2871.	2.8	38

#	Article	IF	Citations
91	Modified release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2855.	3.6	38
92	The Role of 11 Î²-Hydroxysteroid Dehydrogenase in Central Obesity and Osteoporosis. Endocrine Research, 2000, 26, 711-722.	1.2	37
93	Sleep and liver disease: a bidirectional relationship. The Lancet Gastroenterology and Hepatology, 2021, 6, 850-863.	8.1	36
94	Lack of Hexose-6-Phosphate Dehydrogenase Impairs Lipid Mobilization from Mouse Adipose Tissue. Endocrinology, 2008, 149, 2584-2591.	2.8	35
95	A comparative quality assessment of evidenceâ€based clinical guidelines in endocrinology. Clinical Endocrinology, 2013, 78, 183-190.	2.4	35
96	Tissue Specific Regulation of Glucocorticoids in Severe Obesity and the Response to Significant Weight Loss Following Bariatric Surgery (BARICORT). Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1434-1444.	3.6	35
97	Prevalence and severity of nonâ€alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital. Diabetic Medicine, 2018, 35, 89-98.	2.3	35
98	Sex Differences in Hepatic De Novo Lipogenesis with Acute Fructose Feeding. Nutrients, 2018, 10, 1263.	4.1	35
99	Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. European Respiratory Journal, 2008, 32, 1047-1052.	6.7	34
100	Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. The Lancet Gastroenterology and Hepatology, 2022, 7, 755-769.	8.1	34
101	Characterisation of 11Î²-hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat. Journal of Endocrinology, 2007, 192, 279-288.	2.6	32
102	Selective Inhibitors of 11Â-Hydroxysteroid Dehydrogenase Type 1 for Patients With Metabolic Syndrome: Is the Target Liver, Fat, or Both?. Diabetes, 2009, 58, 14-15.	0.6	31
103	Regulation of Lipid Metabolism by Glucocorticoids and 11Î²-HSD1 in Skeletal Muscle. Endocrinology, 2013, 154, 2374-2384.	2.8	30
104	Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 314-326.	3.6	30
105	Extensive weight loss reduces glycan age by altering IgG N-glycosylation. International Journal of Obesity, 2021, 45, 1521-1531.	3.4	29
106	Dysregulation of 11beta-hydroxysteroid dehydrogenases: implications during pregnancy and beyond. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 284-293.	1.5	27
107	SFRP2 Is Associated with Increased Adiposity and VEGF Expression. PLoS ONE, 2016, 11, e0163777.	2.5	27
108	11Î²-HSD1 Modulates the Set Point of Brown Adipose Tissue Response to Glucocorticoids in Male Mice. Endocrinology, 2017, 158, 1964-1976.	2.8	26

#	Article	IF	Citations
109	Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antiviral Therapy, 2009, 14, 1089-1100.	1.0	25
110	The Role of 11ÃŸ-Hydroxysteroid Dehydrogenase 1 in Adipogenesis in Thyroid-Associated Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 398-406.	3.6	25
111	IGFALS Gene Dosage Effects on Serum IGF-I and Glucose Metabolism, Body Composition, Bone Growth in Length and Width, and the Pharmacokinetics of Recombinant Human IGF-I Administration. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E703-E712.	3.6	25
112	Treating Hypertension in Diabetic Nephropathy. Diabetes Care, 2003, 26, 1802-1805.	8.6	24
113	â€œCushingâ€™s disease of the omentumâ€•â€” Fat or fiction?. Journal of Endocrinological Investigation, 2004, 27, 171-174.	3.3	24
114	Longitudinal changes in glucocorticoid metabolism are associated with later development of adverse metabolic phenotype. European Journal of Endocrinology, 2014, 171, 433-442.	3.7	24
115	Cortisol metabolism, postnatal depression and weight changes in the first 12 months postpartum. Clinical Endocrinology, 2016, 85, 881-890.	2.4	24
116	Advanced nonâ€alcoholic fatty liver disease and adipose tissue fibrosis in patients with AlstrÃ¶m syndrome. Liver International, 2016, 36, 1704-1712.	3.9	23
117	Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?. Diabetes, Obesity and Metabolism, 2019, 21, 749-760.	4.4	23
118	Relative Adipose Tissue Failure in AlstrÃ¶m Syndrome Drives Obesity-Induced Insulin Resistance. Diabetes, 2021, 70, 364-376.	0.6	23
119	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Frontline Gastroenterology, 2017, 8, 252-259.	1.8	22
120	Reduced 11Î²-hydroxysteroid dehydrogenase type 1 activity in obese boys. European Journal of Endocrinology, 2007, 157, 319-324.	3.7	21
121	Optimizing human hepatocyte models for metabolic phenotype and function: effects of treatment with dimethyl sulfoxide (DMSO). Physiological Reports, 2016, 4, e12944.	1.7	21
122	Liver biochemical abnormalities in Turner syndrome: A comprehensive characterization of an adult population. Clinical Endocrinology, 2018, 89, 667-676.	2.4	21
123	International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: data from the I-CAH registry. European Journal of Endocrinology, 2021, 184, 553-563.	3.7	21
124	The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. American Journal of Physiology - Renal Physiology, 2020, 319, G345-G360.	3.4	20
125	Is it time for chronopharmacology in NASH?. Journal of Hepatology, 2022, 76, 1215-1224.	3.7	20
126	The Dehydrogenase Hypothesis. Advances in Experimental Medicine and Biology, 2015, 872, 353-380.	1.6	19

#	Article	IF	Citations
127	Recovery of the Hypothalamo-Pituitary-Adrenal Axis After Transsphenoidal Adenomectomy for Nonâ€“ACTH-Secreting Macroadenomas. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5316-5324.	3.6	19
128	Glucocorticoids in pregnancy. Obstetric Medicine, 2020, 13, 62-69.	1.1	17
129	Sex hormones, adiposity, and metabolic traits in men and women: a Mendelian randomisation study. European Journal of Endocrinology, 2022, 186, 407-416.	3.7	17
130	Male 11Î²-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease. Endocrinology, 2016, 157, 3493-3504.	2.8	16
131	AKR1D1 regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells. Journal of Steroid Biochemistry and Molecular Biology, 2019, 189, 218-227.	2.5	16
132	Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure. Clinical Endocrinology, 2019, 90, 440-448.	2.4	16
133	Treatment with PBI-4050 in patients with AlstrÃ¶m syndrome: study protocol for a phase 2, single-Centre, single-arm, open-label trial. BMC Endocrine Disorders, 2018, 18, 88.	2.2	15
134	Hormonal Regulation of Lipogenesis. Vitamins and Hormones, 2013, 91, 1-27.	1.7	15
135	The 5-HT2C receptor agonist meta-chlorophenylpiperazine (mCPP) reduces palatable food consumption and BOLD fMRI responses to food images in healthy female volunteers. Psychopharmacology, 2018, 235, 257-267.	3.1	14
136	The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1. Journal of Steroid Biochemistry and Molecular Biology, 2020, 202, 105724.	2.5	13
137	Accurate nonâ€invasive diagnosis and staging of nonâ€alcoholic fatty liver disease using the urinary steroid metabolome. Alimentary Pharmacology and Therapeutics, 2020, 51, 1188-1197.	3.7	13
138	Short- and long-term glucocorticoid treatment enhances insulin signalling in human subcutaneous adipose tissue. Nutrition and Diabetes, 2011, 1, e3-e3.	3.2	12
139	Differential glucocorticoid metabolism in patients with persistent versus resolving inflammatory arthritis. Arthritis Research and Therapy, 2015, 17, 121.	3.5	12
140	Very low calorie diets are associated with transient ventricular impairment before reversal of diastolic dysfunction in obesity. International Journal of Obesity, 2019, 43, 2536-2544.	3.4	12
141	Association of Weight Changes With Changes in Histological Features and Blood Markers in Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2022, 20, e538-e547.	4.4	12
142	Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis. European Journal of Endocrinology, 2022, 186, 367-377.	3.7	12
143	Increased systemic and adipose 11Î²-HSD1 activity in idiopathic intracranial hypertension. European Journal of Endocrinology, 2022, 187, 323-333.	3.7	11
144	Sodiumâ€glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulinâ€resistant patients without type 2 diabetes. JGH Open, 2020, 4, 433-440.	1.6	10

#	Article	IF	Citations
145	Evidence for a Shift to Anaerobic Metabolism in Adipose Tissue in Efavirenz-Containing Regimens for HIV with Different Nucleoside Backbones. Antiviral Therapy, 2012, 17, 495-507.	1.0	9
146	Increased central adiposity and decreased subcutaneous adipose tissue 11Î²â€hydroxysteroid dehydrogenase type 1 are associated with deterioration in glucose toleranceâ€"A longitudinal cohort study. Clinical Endocrinology, 2019, 91, 72-81.	2.4	9
147	Co-administration of 5Î±-reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3316-e3328.	3.6	9
148	The role of 5-reduction in physiology and metabolic disease: evidence from cellular, pre-clinical and human studies. Journal of Steroid Biochemistry and Molecular Biology, 2021, 207, 105808.	2.5	9
149	Gonadectomy in conditions affecting sex development: a registry-based cohort study. European Journal of Endocrinology, 2021, 184, 791-801.	3.7	9
150	Glucocorticoids regulate AKR1D1 activity in human liver in vitro and in vivo. Journal of Endocrinology, 2020, 245, 207-218.	2.6	9
151	Acute Hypercortisolemia Exerts Depot-Specific Effects on Abdominal and Femoral Adipose Tissue Function. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1091-1101.	3.6	8
152	Human and murine steroid 5Î²-reductases (AKR1D1 and AKR1D4): insights into the role of the catalytic glutamic acid. Chemico-Biological Interactions, 2019, 305, 163-170.	4.0	8
153	AKR1D1 knockout mice develop a sex-dependent metabolic phenotype. Journal of Endocrinology, 2022, 253, 97-113.	2.6	7
154	Clinical practice gaps and challenges in nonâ€alcoholic steatohepatitis care: An international physician needs assessment. Liver International, 2022, 42, 1772-1782.	3.9	7
155	A potential role for hepcidin in obesity-driven colorectal tumourigenesis. Oncology Reports, 2018, 39, 392-400.	2.6	6
156	Learning pharmacokinetic models for in vivo glucocorticoid activation. Journal of Theoretical Biology, 2018, 455, 222-231.	1.7	6
157	Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents. Metabolism Open, 2022, 14, 100177.	2.9	6
158	11Î²-Hydroxysteroid dehydrogenase type 1 as a therapeutic target in the metabolic syndrome. Drug Discovery Today: Therapeutic Strategies, 2005, 2, 93-96.	0.5	5
159	Association between hypercortisolaemia and adipose tissue blood flow in vivo. Lancet, The, 2015, 385, S63.	13.7	5
160	Differential Adipose Tissue Gene Expression Profiles in Abacavir Treated Patients That May Contribute to the Understanding of Cardiovascular Risk: A Microarray Study. PLoS ONE, 2015, 10, e0117164.	2.5	5
161	11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target. Minerva Endocrinologica, 2005, 30, 37-46.	1.8	5
162	Altered cortisol metabolism in individuals with HNF1Aâ€MODY. Clinical Endocrinology, 2020, 93, 269-279.	2.4	4

#	Article	IF	Citations
163	Fighting liver fat. Endocrine Connections, 2020, 9, R173-R186.	1.9	4
164	Glucocorticoid Metabolism and Activation. , 2019, , 90-103.		3
165	Differential activity and expression of human 5Î²-reductase (AKR1D1) splice variants. Journal of Molecular Endocrinology, 2021, 66, 181-194.	2.5	3
166	THE ANDRO-METABOLIC SIGNATURE OF IIH COMPARED WITH PCOS AND SIMPLE OBESITY. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.46-e1.	1.9	2
167	Periâ€operative corticosteroid supplementation for patients on therapeutic glucocorticoids: a national survey. Anaesthesia, 2020, 75, 1396-1398.	3.8	2
168	Gender specific metabolic phenotype in the 5[beta]-reductase knockout mouse. Endocrine Abstracts, 0, , .	0.0	1
169	Is autonomous cortisol secretion sexually dimorphic?. Lancet Diabetes and Endocrinology,the, 2022, 10, 473-475.	11.4	1
170	Effects of glucocorticoids on fat mass and the therapeutic potential of targeting 11Î²-hydroxysteroid dehydrogenase type 1 in obesity. Clinical Lipidology, 2009, 4, 439-447.	0.4	0
171	P86 5Â-reductase-1 knockout promotes steatosis but protects against hepatocarcinogenesis in a murine model of NAFLD. Gut, 2011, 60, A39-A40.	12.1	0
172	The diagnosis of nonâ€alcoholic fatty liver disease: authors' reply. Alimentary Pharmacology and Therapeutics, 2012, 35, 205-206.	3.7	0
173	Cortisol Metabolism as a Regulator of the Tissue-Specific Glucocorticoid Action. , 2017, , 271-301.		0
174	PWE-075â€…Managing nafld via a multidisciplinary clinic approach improves liver health and is cost effective. , 2018, , .		0
175	Author's Reply: Does increased 11 Î² HSDâ€1 activity induce adverse metabolic phenotype only in lean?. Clinical Endocrinology, 2019, 90, 849-850.	2.4	0
176	Editorial: can urineâ€based metabolomics improve diagnosis of advanced fibrosis in NAFLD? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 1205-1206.	3.7	0
177	Response to the Letter: â€œDual-5Î±-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Manâ€• Journal of Clinical Endocrinology and Metabolism, 2016, 101, L48-L49.	3.6	0
178	SP5.1.5 Bariatric surgery is associated with greater survival and metabolic health benefits than conventional medical management in people with NAFLD. British Journal of Surgery, 2021, 108, .	0.3	0